Correlation
The correlation between ADMA and ARQT is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
ADMA vs. ARQT
Compare and contrast key facts about ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ADMA or ARQT.
Performance
ADMA vs. ARQT - Performance Comparison
Loading data...
Key characteristics
ADMA:
1.66
ARQT:
0.83
ADMA:
2.47
ARQT:
1.48
ADMA:
1.31
ARQT:
1.16
ADMA:
3.36
ARQT:
0.61
ADMA:
6.80
ARQT:
3.68
ADMA:
15.70%
ARQT:
13.36%
ADMA:
67.21%
ARQT:
72.04%
ADMA:
-91.28%
ARQT:
-95.02%
ADMA:
-19.34%
ARQT:
-63.03%
Fundamentals
ADMA:
$4.72B
ARQT:
$1.69B
ADMA:
$0.84
ARQT:
-$1.04
ADMA:
10.27
ARQT:
7.92
ADMA:
12.47
ARQT:
11.82
ADMA:
$459.38M
ARQT:
$212.82M
ADMA:
$241.40M
ARQT:
$188.12M
ADMA:
$158.29M
ARQT:
-$106.93M
Returns By Period
In the year-to-date period, ADMA achieves a 15.28% return, which is significantly higher than ARQT's -1.87% return.
ADMA
15.28%
-18.00%
-9.44%
110.32%
113.20%
43.14%
8.67%
ARQT
-1.87%
-7.32%
16.74%
59.14%
-13.32%
-16.44%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ADMA vs. ARQT — Risk-Adjusted Performance Rank
ADMA
ARQT
ADMA vs. ARQT - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
ADMA vs. ARQT - Dividend Comparison
Neither ADMA nor ARQT has paid dividends to shareholders.
Drawdowns
ADMA vs. ARQT - Drawdown Comparison
The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for ADMA and ARQT.
Loading data...
Volatility
ADMA vs. ARQT - Volatility Comparison
The current volatility for ADMA Biologics, Inc. (ADMA) is 14.56%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 15.51%. This indicates that ADMA experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
ADMA vs. ARQT - Financials Comparison
This section allows you to compare key financial metrics between ADMA Biologics, Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ADMA vs. ARQT - Profitability Comparison
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a gross profit of 61.10M and revenue of 114.80M. Therefore, the gross margin over that period was 53.2%.
ARQT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a gross profit of 57.02M and revenue of 65.85M. Therefore, the gross margin over that period was 86.6%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported an operating income of 34.88M and revenue of 114.80M, resulting in an operating margin of 30.4%.
ARQT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported an operating income of -24.53M and revenue of 65.85M, resulting in an operating margin of -37.3%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a net income of 26.90M and revenue of 114.80M, resulting in a net margin of 23.4%.
ARQT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a net income of -25.06M and revenue of 65.85M, resulting in a net margin of -38.1%.